Cabozantinib to be featured in eight presentations

CABOSUN results accepted as late-breaker presentation in oral session at the Presidential Symposium

[LBA30] “CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 Trial.”
Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Session: Presidential session 3
Oral presentation Monday, October 10, 4:30 – 6:10 p.m. CEST, Copenhagen
Note: This is a National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) study.

Poster Discussion
[774PD] “A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.”
Dr. Andrea Borghese Apolo, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Session: Genitourinary Tumours, Non-Prostate
Poster presented Sunday, October 9, 4:30 – 5:30 p.m. CEST, Athens
Note: This is an NCI-CTEP study.

Poster Presentations
[787P] “A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC).”
Dr. Rosa Nadal, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
Session: Genitourinary Tumours, Non-Prostate
Poster presented Sunday, October 9, 1 – 2 p.m. CEST, Hall E
Note: This is an NCI-CTEP study.

[814P] “Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial.”
Dr. Thomas Powles, Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London, GB
Session: Genitourinary Tumours, Non-Prostate
Poster presented Sunday, October 9, 1 – 2 p.m. CEST, Hall E

[815P] “Evaluation of the novel “trial within a trial” design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).”
Colin Hessel, Exelixis, Inc., South San Francisco, California, USA
Session: Genitourinary Tumours, Non-Prostate
Poster presented Sunday, October 9, 1 – 2 p.m. CEST, Hall E

[816P] “Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC).”
Dr. David Cella, Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Session: Genitourinary Tumours, Non-Prostate
Poster presented Sunday, October 9, 1 – 2 p.m. CEST, Hall E

[818P] “Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).”
Dr. Nizar Tannir, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
Session: Genitourinary Tumours, Non-Prostate
Poster presented Sunday, October 9, 1 – 2 p.m. CEST, Hall E

[1421TiP] “A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high grade undifferentiated uterine sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment.”
Dr. Isabelle Ray-Coquard, Cancer Research Center of Lyon, Lyon, France
Session: Basic science
Poster presented Monday, October 10, 1 – 2 p.m. CEST, Hall E
Note: This is an investigator-sponsored trial.

 

Lanreotide (Somatuline^® Autogel^®) will be featured in 6 presentations:

[438P] “Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study”
Dr Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY, USA
Session: Endocrine and neuroendocrine tumours
Poster presented Saturday, October 8, 1 – 2 p.m. CEST, Hall E

[440P] “Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study”
Dr George Fisher. Stanford University School of Medicine, Stanford, CA, USA
Session: Endocrine and neuroendocrine tumours
Poster presented Saturday, October 8, 1-2 p.m. CEST, Hall E

[439P] “Long-term safety/tolerability of lanreotide autogel/depot (LAN) treatment for metastatic intestinal and pancreatic neuroendocrine tumours (NETs): final results of the CLARINET open-label extension (OLE)”
Dr Martyn Caplin, Royal Free Hospital, London, UK
Session: Endocrine and neuroendocrine tumours
Poster presented Saturday, October 8, 1 – 2 p.m. CEST, Hall E

[449TiP] “Safety and Efficacy of Lanreotide Autogel/Depot Every 14 Days for Patients with Pancreatic or Midgut Neuroendocrine Tumours Progressing on Lanreotide Every 28 Days: The Prospective, International CLARINET FORTE Study”
Dr Marianne Pavel. Charité University Medicine, Berlin, Germany
Session: Endocrine and neuroendocrine tumours
Poster presented Saturday, October 8, 1 – 2 p.m. CEST, Hall E

[450TiP] “Safety of lanreotide 120 mg ATG in combination with metformin in patients with advanced well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prospective study: The MetNET-2 trial”
F. De Braud et al.
Session: Endocrine and neuroendocrine tumours
Poster presented Saturday, October 8, 1-2 p.m. CEST, Hall E
Note: This is a National Cancer Institute Milan sponsored study

[451TiP] “Combined Lanreotide Autogel and Temozolomide Therapy in Progressive Neuroendocrine Tumours: The SONNET Study”
Dr Dieter Hörsch, Zentralklinik Bad Berka, Bad Berka, Germany
Session: Endocrine and neuroendocrine tumours
Poster presented Saturday, October 8, 1 – 2 p.m. CEST, Hall E

 

Telotristat ethyl will be featured in one presentation:

[422PD] “Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome”
Dr Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA, USA
Session: Endocrine and neuroendocrine tumours
Poster discussion, Monday, October 10, 11-12 a.m. CEST, Room Berlin

 

In addition, Ipsen supported a collaborative study to understand the epidemiology of NET in  European countries:

[424PD] “Prevalence of gastroenteropancreatic and lung neuroendocrine tumours in the European Union”
A. Bergamasco et al.
Session: Endocrine and neuroendocrine tumours
Poster discussion, Monday, October 10, 11-12 a.m. CEST, Room Berlin

 

Ipsen and Exelixis will host a joint investor / media event on October 10, 2016 at 6:30 p.m. (room 21, 1^st floor, press area, Bella Center). Further information will follow with webcast and conference call details.